The Manchester-based company said the new cash will help it to complete the late-stage development of olorofim, a novel oral antifungal for invasive aspergillosis and other serious fungal ...

Now, its spent some of that budget on a new antifungal from Scynexis that could tackle an emerging multidrug-resistant (MDR) pathogen. The exclusive licensing deal covers Brexafemme (ibrexafungerp ...

Pre-Market: 4:02:11 a.m. EST ...

While the majority of data suggest that the echinocandins have little to no effect on CYP activity, drug-drug interactions seem to suggest that these agents may indeed affect the CYP isoenzyme ...